Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Auction day, See you guys later. Have fun and good luck!
Thanks buddy, Every birthday is a gift.
Every day is a blessing!
Wow, Thats awesome. Not to out do you, I have been sober 36 years.
(interesting,How god has people cross paths)
Like an idiot i still smoke, God bless all of us.
Best thing in my life was getting sober.
The natural high, i have been on for all these years.
Were never reached with booze or drugs
how old? i'm 59 this month!
Thanks for the post!
? $ALTAF You keep putting ATLAF
Wow volume looking great!
Hey bud, Hope all is well with you and yours.
We will try, Market little tough to read right now.
We will survive, God bless Salty!
$TEUM 1.18 0.00 0.00 164,995 1.19 1.22
$TEUM
Shares Outstanding 16.08M
Float 11.4M
52 Week High 11/3/2016 | 5.50
52 Week Low 6/13/2017 | 0.5001
Been over a buck now, for over 10 days!
Yo, Here. Huge upside, $TEUM 1.18 0.00 0.00 69,833 1.26 1.27
Pareteum Awarded $3,500,000 Contract by Leading European Mobile Reseller to Convert Customers to its Own MVNO Brand
22 minutes ago - DJNF
- Pareteum's revenue backlog is now over $100,000,000
NEW YORK, Oct. 31, 2017 /PRNewswire/ -- Pareteum Corporation (NYSE American: TEUM), ("Pareteum" or the "Company"), the rapidly growing mobile Cloud Communications Platform company, today announced that it has been awarded a cloud services contract from a leading European mobile reseller and unified communications supplier which has been servicing some of the largest enterprises in the UK and Europe for over 20 years. The contract is scheduled to add $3,500,000 to Pareteum's $100+ million revenue backlog over a 36 month period with contract deployment planned in the first quarter of 2018.
Pareteum's Global Mobility Cloud Platform enables this new customer to transition some of its reseller customers to their own platform and brand, thus creating new Mobile Virtual Network Operators (MVNOs). Pareteum's customer is utilizing Pareteum's Global Mobility Cloud Platform and connectivity relationships to take control of its offering and its opportunities for growth as it sells to enterprises of all sizes.
"We are delighted to welcome this new customer to our Global Mobility Cloud and expect this agreement to add significantly to our recurring monthly revenues over the term of the contract as traditional mobile users convert to MVNO based on our cloud platform," stated Vic Bozzo Pareteum's CEO. "Backed by two decades of experience working at the intersection of telecom, mobility and the Internet, our customer embraces the idea that telecom and digital ecosystems require secure, universal interactions through any device, anywhere in the world. Pareteum's Global Mobility Cloud Platform provides exactly this, and is helping this service provider to take more control of its customer experience wherever they originate on any network, anywhere."
"The global unified communications market size was estimated at $35.65 billion in 2016 according to Grandview Research. Increasing global expansion of multinational organizations from diverse industry verticals has led to a rising need for communication with geographically dispersed customers and employees. Moreover, the introduction of innovative trends such as Bring Your Own Device (BYOD) among organizations worldwide is expected to drive the demand for such unified communications solutions. Pareteum is helping to accelerate this integration and our global mobility cloud is really providing a single interface to these customers to migrate their online retail VOIP and network resale customers to their own platform," said Hal Turner, Executive Chairman of Pareteum.
About Pareteum Corporation
The mission of Pareteum Corporation (NYSE American: TEUM) is to connect "every person and everything". Organizations use Pareteum to energize their growth and profitability through cloud communication services and complete turnkey solutions featuring relevant content, applications, and connectivity worldwide. By harnessing the value of communications, Pareteum serves retail, enterprise and IoT customers. Pareteum currently has offices in New York, Sao Paulo, Madrid, Barcelona, Bahrain and the Netherlands. For more information please visit: www.pareteum.com.
Forward Looking Statements:
Certain statements contained herein constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to Pareteum's plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about Pareteum's industry, management's beliefs and certain assumptions made by management. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Because such statements involve risks and uncertainties, the actual results and performance of Pareteum may differ materially from the results expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. Unless otherwise required by law, Pareteum also disclaims any obligation to update its view of any such risks or uncertainties or to announce publicly the result of any revisions to the forward-looking statements made here. Additional information concerning certain risks and uncertainties that could cause actual results to differ materially from those projected or suggested in Pareteum's filings with the Securities and Exchange Commission, copies of which are available from the SEC or may be obtained upon request from Pareteum Corporation.
Pareteum Investor Relations Contact:
Ted O'Donnell
Chief Financial Officer
(212) 984-1096
InvestorRelations@pareteum.com
View original content with multimedia:http://www.prnewswire.com/news-releases/pareteum-awarded-3500000-contract-by-leading-european-mobile-reseller-to-convert-customers-to-its-own-mvno-brand-300546049.html
SOURCE Pareteum Corporation
/Web site: http://www.pareteum.com
(END) Dow Jones Newswires
October 31, 2017 08:15 ET (12:15 GMT)
$TRXC 2.87 0.00 0.00 168,896 3.04 3.05
Volume alert, $NVAX 1.02 0.00 0.00 99,380 1.15 1.17
On news, $GERN 2.06 0.00 0.00 62,294 2.26 2.29
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
29 minutes ago - DJNF
Geron Announces Fast Track Designation Granted to Imetelstat for Lower Risk Myelodysplastic Syndromes
Expanded Part 1 of IMerge is Open for Patient Enrollment
MENLO PARK, Calif., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the potential treatment of adult patients with transfusion-dependent anemia due to Low or Intermediate-1 risk myelodysplastic syndromes (MDS) who are non-del(5q) and who are refractory or resistant to treatment with an erythropoiesis stimulating agent (ESA). Imetelstat is a telomerase inhibitor initially developed by Geron and exclusively licensed to Janssen Biotech, Inc. (Janssen) on a worldwide basis. Janssen sponsored the application for Fast Track designation utilizing preliminary data from IMerge, the ongoing clinical trial being conducted by Janssen in lower risk MDS.
The FDA's Fast Track Program is designed to facilitate the development and expedite the review of new drugs that are intended to treat serious conditions and supported by data that demonstrate the potential to address an unmet medical need. Fast Track designation provides opportunities for frequent interactions with FDA review staff, including meetings to discuss the drug's development plan and to ensure the collection of appropriate data needed to support approval. Through the Fast Track Program, a product candidate may be eligible for priority review, if supported by the clinical data, and for the ability to submit completed sections of a New Drug Application (NDA) on a rolling basis as data become available prior to completion of the full application.
Imetelstat Clinical Development in MDS
Imetelstat is being evaluated in an ongoing Phase 2/3 clinical trial (IMerge) in transfusion dependent patients with Low or Intermediate-1 risk MDS who have relapsed after or are refractory to prior treatment with an ESA. IMerge is designed in two parts: Part 1 is a Phase 2, open-label, single-arm design and Part 2 is designed to be a Phase 3, randomized, controlled trial.
As previously announced, 32 patients were enrolled in Part 1 of IMerge, of which a subset of 13 patients had not received prior treatment with either a hypomethylating agent (HMA) or lenalidomide and did not have a del(5q) chromosomal abnormality. As of May 2017, the 13-patient subset showed an increased durability and rate of red blood cell (RBC) transfusion independence (TI) compared to the overall trial population (>=8-week RBC-TI: 53.8% vs 34.4%). Based on these data, Part 1 is being expanded to enroll approximately 20 additional patients who are non-del(5q) and naïve to HMA and lenalidomide treatment to increase the experience and confirm the benefit-risk profile of imetelstat in this refined target patient population. Janssen has opened the expanded Part 1 for patient enrollment. For more information about IMerge, please visit https://clinicaltrials.gov/ct2/show/NCT02598661.
Results for the original 32 patients in Part 1 of IMerge, including hematologic improvement and rate of RBC-TI lasting at least 24 weeks, as well as duration of response and safety information, are expected to be presented at an upcoming major medical conference.
About Imetelstat
Imetelstat (GRN163L; JNJ-63935937) is a potent and specific inhibitor of telomerase that is administered by intravenous infusion. This first-in-class compound, discovered by Geron, is a specially designed and modified short oligonucleotide, which targets and binds directly with high affinity to the active site of telomerase. Preliminary clinical data suggest imetelstat might have disease-modifying activity by inhibiting the progenitor cells of the malignant clones associated with hematologic malignancies in a relatively select manner. Most commonly reported adverse events in imetelstat clinical studies include fatigue, gastrointestinal symptoms and cytopenias. Imetelstat has not been approved for marketing by any regulatory authority.
About the Collaboration with Janssen
On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. Under the terms of the agreement, Geron received an upfront payment of $35 million and is eligible to receive additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, as well as royalties on worldwide net sales. All regulatory, development, manufacturing and promotional activities related to imetelstat are being managed through a joint governance structure, with Janssen responsible for these activities.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
Use of Forward-Looking Statements
Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that statements in this press release regarding: (i) continued conduct by Janssen of IMerge and any future clinical trials of imetelstat; (ii) expanding enrollment to Part 1 of IMerge in a refined target patient population; (iii) the timing for enrollment to begin for the expanded Part 1 of IMerge; (iv) any future presentation of data from current clinical trials of imetelstat by Janssen at a major medical conference; (v) potential outcomes of any data reviews conducted by Janssen for IMerge; (vi) the safety and efficacy of imetelstat; (vii) that approximately 20 additional patients in IMerge will be sufficient for decision-making; (viii) potential receipt by Geron of additional payments up to a potential total of $900 million for the achievement of development, regulatory and commercial milestones, and royalties from sales of imetelstat; and (ix) other statements that are not historical facts, constitute forward-looking statements. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (i) whether Janssen decides to continue to conduct IMerge; (ii) whether imetelstat is safe and efficacious and will succeed in IMerge by overcoming all of the clinical safety and efficacy, technical, scientific, manufacturing and regulatory challenges; (iii) whether the FDA or other health authorities permit IMerge to continue to proceed under the existing protocols or any amendments thereto; (iv) Janssen's ability to collect additional and more mature data from current clinical trials of imetelstat; (v) Geron's dependence on Janssen for the development, regulatory approval, manufacture and commercialization of imetelstat, including the risks that if Janssen were to breach or terminate the collaboration agreement or otherwise fail to successfully develop and commercialize imetelstat and in a timely manner, or at all, Geron would not obtain the anticipated financial and other benefits of the collaboration agreement with Janssen and the clinical development or commercialization of imetelstat could be delayed or terminated; (vi) whether any future efficacy or safety results from any clinical trial of imetelstat may cause the benefit/risk profile of imetelstat to become unacceptable; and (vii) whether patent coverage of imetelstat enables Janssen to successfully commercialize imetelstat. Additional information on the above-stated risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron's periodic reports filed with the Securities and Exchange Commission under the heading "Risk Factors," including Geron's quarterly report on Form 10-Q for the quarter ended June 30, 2017. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events or circumstances.
CONTACT:
Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com
media@geron.com
(END) Dow Jones Newswires
October 31, 2017 07:30 ET (11:30 GMT)
Now your talking, lithium lithium lithium .lol
$ALTAF on watch!
Honest opinion, I like the float. But to low of volume.
No catalyst in sight, Hovering around 52 week and way beyond.
Not enough upside potential. Hope this helps.
Thanks for asking!
I think $ATPT going to be a great play, No worries here!
Hi guys, welcome back. GO ONCI!
lol, go $atpt
Loading zone, $ATPT!!!!!!
Good morning dip & rippers!
lol, hope so. go $ABVG
Well, You can wait for 3's, or buy at 4.
or then chase to 5's and beyond.
Go $ABVG
Have a nice weekend Curly and $ABVGers!
Have a great weekend everyone!
$ATPT, WEEEEEEEEEEEEEEEE
$ABVG looking good from here!
Hey guys, Also check out $ABVG @.0004 lot of great thing coming down the pike!
I think i will buy a few more today!
Yep, Great things are coming with $ABVG!
I hope $ATPT is one of those moments.
Life is not measured by the number of breaths you take, but by the moments that take your breath away--Wows happen!!!
$ATPT one or two ticks a day, I'll take it!
$PERI 1.12 0.00 0.00 122,431 1.15 1.16
Perion Network to Announce Third Quarter 2017 Financial Results on November 9, 2017
1 hour 53 minutes ago - DJNF
TEL AVIV, Israel & NEW YORK--(BUSINESS WIRE)--October 26, 2017--
Perion Network Ltd. (NASDAQ:PERI), today announced that it will release its financial results for the third quarter ended September 30, 2017, on November 9, 2017 prior to the financial markets open.
Perion management will host a conference call to discuss the results at 10 a.m. ET that day.
Details are as follows:
-- Conference ID: 8570941
-- Dial-in number from within the United States: 1-888-430-8709
-- Dial-in number from Israel: 1-80-925-8243
-- Dial-in number (other international): 1-719-325-2456
-- Playback available until November 16, 2017 by calling 1-844-512-2921
(United States) or1-412-317-6671 (international). Please use PIN code
8570941 for the replay.
-- Link to the live webcast accessible at https://www.perion.com/ir-info/
About Perion Network Ltd.
Perion is a global technology company that delivers advertising solutions to brands and publishers. Perion is committed to providing data-driven execution, from high-impact ad formats to branded search and a unified social and mobile programmatic platform. More information about Perion may be found at www.perion.com, and follow Perion on Twitter @perionnetwork.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005599/en/
CONTACT: Perion Network Ltd.
Investor relations
Vicky Batkin
+972 (73) 398-1000
perion.investor.relations@perion.com
SOURCE: Perion Network Ltd.
Copyright Business Wire 2017
(END) Dow Jones Newswires
October 26, 2017 07:00 ET (11:00 GMT)
Pdx Partners, Inc. ( (PDXP)
0.0041 ? 0.0028 (215.38%)
Volume: 20,722,156
0.0032 ? 0.0019 (146.15%)
$NSPR 0.445 0.00 0.00 33,760 0.499 0.51
New York Stock Exchange Accepts InspireMD's Plan to Regain Compliance
23 hours 10 minutes ago - DJNF
New York Stock Exchange Accepts InspireMD's Plan to Regain Compliance
TEL AVIV, ISRAEL--(Marketwired - Oct 24, 2017) - InspireMD, Inc. (NYSE AMER: NSPR) (NYSE AMER: NSPR.WS) ("InspireMD" or the "Company"), a leader in embolic prevention systems (EPS) / thrombus management technologies and neurovascular devices, today announced that the New York Stock Exchange has accepted the Company's plan to regain compliance with the NYSE American's stockholder's equity continued listing standard (Part 10, Section 1003(a)(iii)). As previously disclosed, the NYSE American notified the Company on August 17, 2017, that it had fallen below the NYSE's continued listing standards.
Based upon a review of the compliance plan and information submitted by the Company, the Exchange determined that the Company made a reasonable demonstration of its ability to make substantial progress toward regaining compliance with Section 1003(a)(iii) of the Company Guide by February 17, 2018.
The Company will be subject to periodic review by the exchange staff during the period covered by the plan. Failure to make progress consistent with the plan or to regain compliance with the continued listing standards by the end of the plan period could result in the Company's shares being delisted from the Exchange.
About InspireMD, Inc.
InspireMD seeks to utilize its proprietary MicroNet(TM) technology to make its products the industry standard for embolic protection and to provide a superior solution to the key clinical issues of current stenting in patients with a high risk of distal embolization, no reflow and major adverse cardiac events.
InspireMD intends to pursue applications of this MicroNet technology in coronary, carotid (CGuard(TM)), neurovascular, and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE American under the ticker symbol NSPR and certain warrants are quoted on the NYSE American under the ticker symbol NSPR.WS.
Forward-looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans, " "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multinational companies, (v) product liability claims, (vi) product malfunctions, (vii) our limited manufacturing capabilities and reliance on subcontractors for assistance, (viii) insufficient or inadequate reimbursement by governmental and other third party payers for our products, (ix) our efforts to successfully obtain and maintain intellectual property protection covering our products, which may not be successful, (x) legislative or regulatory reform of the healthcare system in both the U.S. and foreign jurisdictions, (xi) our reliance on single suppliers for certain product components, (xii) the fact that we will need to raise additional capital to meet our business requirements in the future and that such capital raising may be costly, dilutive or difficult to obtain and (xiii) the fact that we conduct business in multiple foreign jurisdictions, exposing us to foreign currency exchange rate fluctuations, logistical and communications challenges, burdens and costs of compliance with foreign laws and political and economic instability in each jurisdiction. More detailed information about the Company and the risk factors that may affect the realization of forward looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
Investor Contacts:
InspireMD, Inc.
Craig Shore
Chief Financial Officer
Phone: 1-888-776-6804 FREE
Email: craigs@inspiremd.com
Crescendo Communications, LLC
David Waldman
Phone: (212) 671-1021
Email: NSPR@crescendo-ir.com
(MORE TO FOLLOW) Dow Jones Newswires
October 24, 2017 09:47 ET (13:47 GMT)
I added more $ABVG yesterday @ .0004!
Yo, morning buddy. Waiting patiently, Good things are happening $ABVG!
On watch, $CEMP 2.65 0.00 0.00 10,100 2.70 2.80
Thanks, I think. Just updating my many post on $ATPT
IMO its going to work itself to .005 + Maybe a penny!
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135522528